Background ExteNET showed that 1 year of neratinib, an irreversible pan-HER tyrosine
kinase inhibitor, significantly improves 2-year invasive disease-free survival after trastuzumab-…

PURPOSE Pembrolizumab monotherapy is standard first-line therapy for metastatic non–small-cell
lung cancer (NSCLC) with programmed death ligand 1 (PD-L1) tumor proportion …

Background Chordoma is a rare malignant tumor of the skull base and axial skeleton, with
an incidence of less than 0.1/100,000 per year. Patients with advanced chordoma have a …

Background: Gastric carcinoma (GC) patients usually present with locally advanced or
metastatic disease; therefore treatment aim is mainly palliation. In this study our purpose is to …

Objective We changed our surgical approach to malignant pleural mesothelioma (MPM) in
August 2011 and adopted pleurectomy and decortication (PD) instead of extrapleural …

Background The use of highly toxic drugs in cancer treatment and supportive care medications
exposes patients to an increased number of drug-related problems (DRPs). Clinical …

Lorlatinib is a third-generation tyrosine-kinases inhibitor (TKI) targeting ALK/ROS1 fusions.
The FDA has approved lorlatinib for TKI-pretreated ALK(+) NSCLC, while its approval for …

Introduction Inflammatory myofibroblastic tumor is a rare disease which is typically seen in
children and young adults. Approximately half of the inflammatory myofibroblastic tumors …

Tumor immune microenvironment (TIME) is a significant prognostic parameter for triple
negative breast carcinomas (TNBC) due to being a target for immunotherapeutic agents and its …

Purpose Neoadjuvant chemotherapy is the standard front-line treatment modality in locally
advanced breast cancer. Achieving pathological complete response (pCR) is a significant …